A Phase I Study of Ganetespib and Ziv‐Aflibercept in Patients with Advanced Carcinomas and Sarcomas

LESSONS LEARNED. The combination of the antiangiogenic agent ziv‐aflibercept and the heat shock protein 90 inhibitor ganetespib was associated with several serious and unexpected adverse events and was not tolerable on the dosing schedule tested. Studies such as these emphasize the importance of con...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Meehan, Robert, Kummar, Shivaani, Do, Khanh, O'Sullivan Coyne, Geraldine, Juwara, Lamin, Zlott, Jennifer, Rubinstein, Larry, Doroshow, James H., Chen, Alice P.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2018
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6291327/
https://ncbi.nlm.nih.gov/pubmed/29853657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0203
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados